CONTINUING LEGAL EDUCATION CREDIT SELF REPORTING ATTENDANCE AND EVALUATION FORM — TWENTY-FIFTH PHARMACEUTICAL AND MEDICAL DEVICE ETHICS AND COMPLIANCE CONGRESS

The **Pharmaceutical and Medical Device Ethics and Compliance Congress** is an approved provider for **PA MCLE** Live and Distance Learning courses. As such, the Congress will submit CLE credit requests to PA MCLE for attorneys licensed in Pennsylvania.

The Congress has been authorized to offer **23 Live CLE Credits** and **18 Distance Learning Credits** for Pennsylvania.

To qualify for CLE credit submission to PA MCLE and to receive a Congress Certificate of Attendance, attorneys must:

- Pay a **$100 fee** to the Pharma Congress at **www.pharmacongress.com**
- Complete and sign the **Continuing Legal Education Credit Self-Reporting Attendance and Evaluation Form** for the Congress.

Payment and the completed form must be emailed to **Cindy@ghccongress.com** by **November 30, 2024**.

For attorneys licensed outside Pennsylvania, the Congress will post attendance records with PA MCLE and issue a Certificate of Attendance, which may be used to self-report to other states. However, the Congress does not guarantee acceptance of this certificate by other states for CLE credit.

PERSONAL CONTACT INFORMATION

COMPLETE THE FOLLOWING:

NAME

SIGNATURE OF REGISTRANT - REQUIRED

JOB TITLE

STATE WHERE YOU PRACTICE

ADDRESS

CITY/STATE/ZIP

TELEPHONE

E-MAIL

PA BAR NUMBER IF FROM PA

NUMBER OF HOURS YOU PARTICIPATED

SELF REPORTING OF ATTENDANCE AT THE TWENTY-FIFTH PHARMA CONGRESS

Please mark those Pharma/Device Congress sessions below that you attended.

DAY I: MONDAY, OCTOBER 28, 2024

MINI SUMMITS GROUP 1

- ☐ MINI-SUMMIT 1: Federal Criminal and Civil Enforcement: Recent Highlights and Emerging Issues — 50 min.
- ☐ MINI-SUMMIT 2 : Enhancing Compliance and Overcoming Challenges under Corporate Integrity Agreements (CIA) through AI and Automation — 50 min.
- ☐ MINI-SUMMIT 3: Fostering a Speak Up Culture — 50 min.
- ☐ MINI-SUMMIT 4: Presenting to Senior Executives Effectively — 50 min.

MINI SUMMITS GROUP 2

- ☐ MINI-SUMMIT 5: Interactions Between Sales and Medical Affairs — 50 min.
- ☐ MINI-SUMMIT 6: Benchmarking and Brainstorming regarding Evolving Regulator Expectations relating to Off-Channel Communication — 50 min.
- ☐ MINI-SUMMIT 7: OIG New General Compliance Program Guidance — 50 min.
- ☐ MINI-SUMMIT 8: Update on Medical Device Regulatory and Enforcement Actions — 50 min.
- ☐ MINI-SUMMIT 9: Compliance Governance and Board of Directors — 50 min.
- ☐ MINI-SUMMIT 10: Health Equity Initiatives—Compliance Considerations — 50 min.

MINI SUMMITS GROUP 3

- ☐ MINI-SUMMIT 11: Targeted, Tailored, True-to-Life: How DOJ Guidance Should Shape Your Compliance Training — 50 min.
- ☐ MINI-SUMMIT 12: Responsible AI at the Cusp of Scale — 50 min.
- ☐ MINI-SUMMIT 13: Hot Topics and Compliance Oversight in the Research and Development Area — 50 min.
- ☐ MINI-SUMMIT 14: Recent Developments in Enforcement Actions — 50 min.
- ☐ MINI-SUMMIT 15: Balancing Compliance and Legal Roles and Responsibilities — 50 min.
- ☐ MINI-SUMMIT 16: Risk-Based Compliance Audits: Prioritizing What Matters Most — 50 min.
- ☐ MINI-SUMMIT 17: ESG Overload—A CCO's Guide to a Balanced Program Implementation — 50 min.

MINI SUMMITS GROUP 4

- ☐ MINI-SUMMIT 18: Compliance Training on the Digital Frontier — 50 min.
- ☐ MINI-SUMMIT 19: Substance over Form: Practical Approaches to Enterprise Risk Management (ERM) — 50 min.
- ☐ MINI-SUMMIT 20: Patient Support Programs and Patient Access Programs—A Look at the Evolution, Risks, and Enforcement Activity — 50 min.
- ☐ MINI-SUMMIT 21: AI and Compliance Analytics: Real Case Studies for Managing HCP, HCO and Third-Party Risk — 50 min.
- ☐ MINI-SUMMIT 22: Beyond Sales Representatives and MSLs: Considerations for Other Field-Based Roles — 50 min.
- ☐ MINI-SUMMIT 23 : Fair Market Value: Navigating the Ongoing Changes in HCP Compensation Compliance — 50 min.

MINI SUMMITS GROUP 5

- ☐ MINI-SUMMIT 24: Is Bigger Always Bad? Assessing Developing FTC Antitrust Enforcement Trends in Life Sciences — 50 min.
- ☐ MINI-SUMMIT 25: Compliance Considerations for Rare Disease — 50 min.
- ☐ MINI-SUMMIT 26: Change Management for Compliance Program Transformation — 50 min.

OPENING PLENARY SESSION

- ☐ Keynote Address: Brent Saunders — 30 min.
- ☐ Keynote Annual OIG Update: Mary Riordan — 45 min.
- ☐ Keynote Annual FDA Update: Katie Gray — 30 min.
- ☐ Keynote Fireside Chat: Myrtle Potter — 30 min.
- ☐ The Implications of AI for Lifesciences Ethics and Compliance Programs — 30 min.
- ☐ Chief Compliance Officer Fireside Chat — 60 min.

DAY II: TUESDAY, OCTOBER 29, 2024

CHIEF COMPLIANCE OFFICER ROUNDTABLE

(PCF Sponsored Special Closed Morning Session, Invitation-only)

- ☐ Behind the Scenes: Evaluating and Presenting Compliance Program Effectiveness to Judges, Juries and Regulators — 45 min.
- ☐ DOJ's Recently Announced Pilot Programs and ECCP Updates — What CCO's Need to Know! — 45 min.
- ☐ How Do you Optimize your Resources to Enhance your Compliance Program? — 45 min.
- ☐ Looking Beyond the CCO Role: Making a Bigger Impact through Board Leadership — 45 min.
- ☐ CCO Exchange Open Forum & Benchmarking — 25 min.

MINI SUMMITS GROUP 6

- ☐ MINI-SUMMIT 27: Service Fees: Hidden Compliance Risks and Downstream Market Access and Government Price Reporting Implications — 50 min.
- ☐ MINI-SUMMIT 28 : Government Programs and Compliance Office Oversight — 50 min.
- ☐ MINI-SUMMIT 29: Advancing Risk Management: A call to action for Integrated Risk Management (IRM) in Pharma — 50 min.
- ☐ MINI-SUMMIT 30: Attention Please! Elevating E&C Learning & Engagement in the Age of Distraction — 50 min.
- ☐ MINI-SUMMIT 31: Key Learnings from CMS Audits — 50 min.
- ☐ MINI-SUMMIT 32: Exploring Risks and Enforcement Trends for Buy-and-Bill Drugs — 50 min.

MINI SUMMITS GROUP 7

- ☐ MINI-SUMMIT 33: Global Compliance Considerations for Designing Patient Support Programs — 50 min.
- ☐ MINI-SUMMIT 34 : Qui Tam Declinations— Analysis and Trends When DOJ Declines to Intervene — 50 min.
- ☐ MINI-SUMMIT 35: Privacy Top-Ten: Strategies and Tactics to Address Operational Impacts of the Evolving Privacy Landscape — 50 min.
- ☐ MINI-SUMMIT 36: Hot Topics in State Law Compliance — 50 min.
- ☐ MINI-SUMMIT 37: The Latest and Greatest in Enforcement and Guidelines for Social Media and Influencers — 50 min.
- ☐ MINI-SUMMIT 38: Compliance Considerations for Genetic Testing — 50 min.
- ☐ MINI-SUMMIT 39: HCP Expense Auditing and Monitoring — 50 min.

MINI SUMMITS GROUP 8

- ☐ MINI-SUMMIT 40: The Role of Technology and Process Enhancements for Effective ABAC Third Party Vendor Diligence — 50 min.
- ☐ MINI-SUMMIT 41: Intersecting Reforms Affecting Drug Pricing — 50 min.
- ☐ MINI-SUMMIT 42: Best Practices in Investigations — 50 min.
- ☐ MINI-SUMMIT 43: Detecting Bias in your AI Tools — 50 min.
- ☐ MINI-SUMMIT 44 : Evolving Risks in Medical Affairs — 50 min.
- ☐ MINI-SUMMIT 45: US Trends and Updates in HCP Spend Transparency and Drug Pricing Transparency — 50 min.
- ☐ MINI-SUMMIT 46: Analytics and Monitoring: Understanding the Risks and Underlying Complexity of Today's Copay Program Landscape — 50 min.

MINI SUMMITS GROUP 9

- ☐ MINI-SUMMIT 47 : Lessons from Spend Transparency and Their Direct Application to Pricing Transparency — 50 min.
- ☐ MINI-SUMMIT 48: State Law Updates— 2024 Recap and 2025 — 50 min.
- ☐ MINI-SUMMIT 49: Addressing Nuances in Third-Party Risk Management for Medical Devices — 50 min.
- ☐ MINI-SUMMIT 50: Market Access—Compliance Considerations When Resolving Disputes — 50 min.
- ☐ MINI-SUMMIT 51: Negotiating DOJ expectations and business challenges while creating a "Culture of Compliance" — 50 min.

CLOSING PLENARY SESSION

- ☐ DOJ Keynote Fireside Chat — 45 min.
- ☐ Reflections on the 25-Year Congress Anniversary — 45 min.
- ☐ Updates from AdvaMed, BIO and PhRMA — 30 min.
- ☐ Investigations, Enforcement and Prosecutions Roundtable — 45 min.
- ☐ Perspectives from DOJ, HHS-OIG, and the Relators Bar on How Compliance Departments Can Effectively Prevent and Help Respond to Qui Tam Whistleblower Suits — 30 min.
- ☐ The Art of Storytelling—Effectively Conveying the Value of Compliance Beyond Activities and Data — 30 min.

DAY III: WEDNESDAY, OCTOBER 30, 2024

INDUSTRY-ONLY COMPLIANCE BEST PRACTICES THINK TANK

- ☐ **Industry-Only Welcome and Introductions and Antitrust Admonition** — **15 min.**
- ☐ **Responsible AI in Action: Real Business Strategies and Mitigation Examples** — **45 min.**
- ☐ **Benchmarking and Q&A Open Forum** — **45 min.**
- ☐ **Compliance Lessons Learned for Cross-Industry Insights** — **30 min.**
- ☐ **Hot Topic Table Discussions** — **60 min.**
- ☐ **Final Open Forum** — **25 min.**

EVALUATION FORM FOR THE PHARMA/DEVICE CONGRESS

You must also complete the following Pharma/Device Congress evaluation form:

	Failed to Meet Expectations	Needs Improvement	Met Expectations	Exceded Expectations	Excellent
Overall Quality	☐	☐	☐	☐	☐
Powerpoints	☐	☐	☐	☐	☐
Speakers	☐	☐	☐	☐	☐
Ease of Use	☐	☐	☐	☐	☐

EXECUTION OF THE CONTINUING LEGAL EDUCATION CREDIT SELF REPORTING ATTENDANCE AND EVALUATION FORM FOR THE PHARMA CONGRESS

By executing this self-reporting form, the attorney hereby warrants that the information provided herein is complete, true and correct.

Executed by: _____ **Date:** _____

Payment must be made and the completed and executed form submitted via email to **Cindy@ghccongress.com** no later than **November 30, 2024.**